News

Public · Published

ADUS: Revenue rose 7%; adjusted EBITDA grew 13.5%, with AccentCare deal pending

ADUS reported third-quarter revenue up 7.0% year over year and adjusted EBITDA, a measure of operating earnings before certain costs, up 13.5%. Net income and adjusted earnings per share also increased. Personal care led growth, and a roughly $275 million AccentCare personal care acquisition is pending.

Published:

Updated:

What happened

ADUS reported third-quarter revenue up 7.0% year over year and adjusted EBITDA, a measure of operating earnings before certain costs, up 13.5%. Net income and adjusted earnings per share also increased. Personal care led growth, and a roughly $275 million AccentCare personal care acquisition is pending.

Confirmed

Global impact / market context

Growth in personal care and stronger reported earnings may support ADUS’s ability to fund operations and investment. If completed, the acquisition would add personal care business, potentially expanding revenue while also requiring cash or borrowed money; its financial effect depends on deal terms and performance.

Analyst inference

The supplied update combines operating growth with a pending acquisition, so investors face two distinct drivers: recent results and a possible change in business scale. The article gives no deal timing, financing details, or forecast, limiting conclusions about future earnings or cash needs.

Analyst inference

What to watch

  1. Watch for the next company update on the roughly $275 million AccentCare acquisition, including whether it closes and when the added personal care business enters reported results. Analyst inference
  2. Look for disclosed financing and transaction terms; these would clarify how much cash ADUS may use, whether it borrows money, and any resulting costs. Analyst inference
  3. Track whether personal care continues leading growth and whether revenue, adjusted EBITDA, net income, and adjusted earnings per share sustain their reported year-over-year increases. Analyst inference

Evidence

  • Original source link unavailable